SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

HTG Molecular Diagnostics, Inc. HTGMQ OTC

Other OTC • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

HTG Molecular Diagnostics, Inc. (HTGMQ) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $6M, -26.6%/yr average growth. Net income is $22M (loss), growing at -5.4%/yr. Net profit margin is -339.2% (negative). Gross margin is 28.2% (-25.4 pp trend).

Balance sheet: total debt is $5M against $5M equity (Debt-to-Equity (D/E) ratio 0.9, moderate). Current ratio is 1.89 (strong liquidity). Debt-to-assets is 27.2%. Total assets: $18M.

Analyst outlook: 1 / 1 analysts rate HTGMQ as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 14/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

HTGMQ SharesGrow Score Overview

38/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 14/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HTGMQ

No analyst coverage available for this stock.

HTGMQ: -26.6%/yr revenue is, -5.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet HTGMQ: Debt-to-Equity (D/E) ratio 0.9 (moderate), Current ratio is 1.89 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

HTGMQ: Gross margin is 28.2% (-25.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 14/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate HTGMQ as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

HTGMQ: Net profit margin is -339.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0001-0.0001

Volume125

Avg Volume (30D)251

Market Cap$221.00

Beta (1Y)2.76

Share Statistics

EPS (TTM)-24.28

Shares Outstanding$889.28K

IPO Date2015-05-06

Employees53

CEOJohn L. Lubniewski

Financial Highlights & Ratios

Revenue (TTM)$6.37M

Gross Profit$1.79M

EBITDA$-20.24M

Net Income$-21.59M

Operating Income$-20.83M

Total Cash$12.21M

Total Debt$4.83M

Net Debt$-7.38M

Total Assets$17.78M

Price / Earnings (P/E)-0

Price / Sales (P/S)0

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS40434H3021

Price Chart

HTGMQ

HTG Molecular Diagnostics, Inc. ↗ · Other OTC

Healthcare • Medical - Diagnostics & Research

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message